Age 18-75 years at the time of signing Informed Consent Form and willingness to comply with study protocol procedures
Previously untreated participants with CD20-positive DLBCL
IPI score 2-5
ECOG Performance Status of 0, 1, or 2
Life expectancy ≥ 6 months
You may not be if
Contraindication to any of the individual components of R-CHOP or Obutinib or Decitabine or Lenalidomide or Chidamide
Have received systemic or local treatment including chemotherapy in the past
Have received autologous stem cell transplantation in the past
Past medical history of other malignant tumors, except basal cell carcinoma of the skin and cervical cancer in situ
Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulopathy, connective tissue diseases, severe infectious diseases and other diseases
Primary central nervous system lymphoma
Left ventricular ejection fraction ≦50%
Other concurrent and uncontrolled situation which will affect the patient's medical status based on researchers' decision
Any of the following abnormal laboratory values (unless any of these abnormalities are due to underlying lymphoma):
* ANC \< 1.0 x 10\^9/L
* PLT \< 75 x 10\^9/L
* Hb \< 100g/L
* Serum AST and ALT ≥ 2.5 x ULN
* Total bilirubin ≥ 1.5 x ULN
* Serum creatinine ≥ 1.5 x ULN
Psychiatric patients or other patients who are known or suspected to be unable to fully accomplish with the research protocol
Pregnant or lactating women
Patients with positive HbsAg test results need to undergo HBV-DNA test and can be admitted to the group after turning negative. In addition, if the HBsAg test result is negative, but the HBcAb test is positive (regardless of the HBsAb status), HBV-DNA is also required；if the result is positive, patients also need to be treated to become negative before entering the group
Patients living with HIV
Clareo Health | Dynamic CtDNA-guided Targeted Therapy in DLBCL
